News

November 14, 2018November 14, 2018

FDA Approves Keytruda for Liver Cancer Patients Who Had Received Nexavar

News

The U.S. Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as a treatment for patients with hepatocellular carcinoma (HCC) — the most common type of liver cancer — who previously ... Read more

November 13, 2018November 13, 2018

FDA Approves Keytruda-Chemotherapy Combo as First-line Therapy for NSCLC

News

Keytruda (pembrolizumab) can now be used in combination with chemotherapy — Paraplatin (carboplatin) plus Taxol (paclitaxel) or Abraxane (nab-paclitaxel) — as first-line therapy for patients with metastatic squamous non-small cell lung cancer ... Read more

November 9, 2018November 9, 2018

Keytruda Elicits Complete Response in 40% of Group of High-risk Bladder Cancer Patients, Early Phase 2 Trial Data Show

News

The immune checkpoint inhibitor Keytruda (pembrolizumab) completely eliminated tumors in almost 40% of a group of bladder cancer patients in an ongoing Phase 2 trial, Merck (known as MSD ... Read more

November 7, 2018November 7, 2018

CHMP Favors EU Approval of Keytruda for Advanced Melanoma Patients with Complete Tumor Resection

News

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), has recommended the approval of Keytruda (pembrolizumab) for the treatment of advanced melanoma ... Read more

November 6, 2018November 6, 2018

SQZ Biotech and Roche Expand Collaboration to Develop Cell Therapies for Cancer Patients

News

SQZ Biotech and Roche are expanding their collaboration to jointly develop and market cancer treatments based on antigen-presenting cells (APCs). According to SQZ, the partnership combines the expertise of ... Read more

November 2, 2018November 2, 2018

Keytruda-Inlyta Combo Extends Survival in Advanced Renal Cell Carcinoma Patients, Phase 3 Trial Shows

News

A combination of Keytruda (pembrolizumab) and Inlyta (axitinib) significantly extended the lives of patients with advanced renal cell carcinoma (RCC) and delayed disease progression or death, according to a Phase 3 clinical ... Read more

October 31, 2018October 31, 2018

Immunotherapy Particularly Effective Against Aggressive Hereditary Melanoma, Study Reports

News

Patients with hereditary melanoma associated with mutations in the CDKN2A gene respond well to immunotherapy, possible due to an increased mutational load in these tumors, a study suggests. The ... Read more

October 30, 2018October 30, 2018

Opdivo Fails to Extend Survival in SCLC Patients in Phase 3 Trial, Bristol-Myers Squibbs Reports

News

Bristol-Myers Squibb‘s immune checkpoint inhibitor Opdivo (nivolumab) is no better than standard chemotherapy at extending the lives of patients with small cell lung cancer (SCLC) who failed prior platinum-based ... Read more

October 26, 2018

Opdivo-Yervoy Combo Shows Potential as First-line Treatment for Certain Colorectal Cancers

News

A combination of Bristol-Myers Squibb‘s Opdivo (nivolumab) and low-dose Yervoy (ipilimumab) induced promising and durable response rates in metastatic colorectal cancer patients with certain genetic abnormalities who had not received ... Read more

October 24, 2018

Keytruda Improves Survival in Patients with Relapsed or Metastatic Head, Neck Cancer, Interim Data Show

News

First-line treatment with Keytruda (pembrolizumab) — alone or in combination with standard chemotherapy — significantly prolongs survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), ... Read more

Pin It on Pinterest